Bio-Rad Laboratories, Inc. (NYSE: BIO) is a Healthcare company (Medical - Devices) with a market capitalization of $9.6B. The Maz Rating grades it against the other companies in its sector.
Bio-Rad Laboratories, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $358.19, Bio-Rad Laboratories, Inc. trades at 9.4x trailing earnings, 3.7x sales and 1.3x book value, with an EV/EBITDA of 7.1. Over the last twelve months it generated about $2.6B of revenue and $1.0B of net income. It runs a gross margin of 51.3%, an operating margin of 4.6% and a net margin of 39.5%. It shows return on equity of 14.1%, return on invested capital of 0.9% and a free cash flow yield of 3.4%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 3.18. Over the past 52 weeks the share price ranged from $236.73 to $396.23, with a beta of 1.06.
Bio-Rad Laboratories, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 1 Strong Buy, 7 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.